| Nadir PSA < 0.06 ng/mL (n = 157) | Nadir PSA ≥ 0.06 ng/mL (n = 47) |  | P value | |
---|---|---|---|---|---|
N | % | N | % | ||
Age: ≤ 70 years | 86 | 54.8 | 26 | 55.3 | 0.948 |
 > 70 years | 71 | 45.2 | 21 | 44.7 | |
GS: ≤ 7 | 68 | 43.3 | 16 | 34.0 | 0.257 |
8–10 | 89 | 56.7 | 31 | 66.0 | |
Stage: T1-T2 | 93 | 60.4 | 21 | 46.7 | 0.102 |
T3–T4 | 61 | 39.6 | 24 | 53.3 | |
PSA at presentation: ≤ 20 ng/mL | 83 | 53.2 | 19 | 40.4 | 0.125 |
 > 20 ng/mL | 73 | 46.8 | 28 | 59.6 | |
Duration of ADT (months) | Â | Â | Â | ||
Mean | 21.5 | 20.2 | 0.493 | ||
Median (IQR) | 24.0 (9–36) | 18.5 (8–36) |  | ||
Duration of ADT | Â | Â | Â | ||
 ≤ 6 months | 36 (23.4) | 10 (21.7) | 0.495 | ||
 ≤ 9 months | 39 (25.3) | 13 (28.3) | 0.412 | ||
 ≤ 12 months | 48 (31.2) | 15 (32.6) | 0.494 | ||
 ≤ 18 months | 54 (35.1) | 24 (52.2) | 0.028 | ||
 ≤ 24 months | 103 (66.9) | 28 (60.9) | 0.280 | ||
 > 24 months | 51 (33.1) | 18 (39.1) | 0.280 | ||
Missing | 3 (1.9%) | 1 (2.1%) | Â | ||
Mean RT dose (Gy) | 73.8 (Range 70–78) | 73.1 (Range 70–78) | 0.113 | ||
Time to nPSA (months Median (IQR) | 6.0 (3.2–10.0) | N/A* |  |